Cancer As a Metabolic Disorder

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163079

Authors

Jones Gyamfi

Jinyoung Kim

Junjeong Choi

Affiliations

Soon will be listed here.

Abstract

Cancer has long been considered a genetic disease characterized by a myriad of mutations that drive cancer progression. Recent accumulating evidence indicates that the dysregulated metabolism in cancer cells is more than a hallmark of cancer but may be the underlying cause of the tumor. Most of the well-characterized oncogenes or tumor suppressor genes function to sustain the altered metabolic state in cancer. Here, we review evidence supporting the altered metabolic state in cancer including key alterations in glucose, glutamine, and fatty acid metabolism. Unlike genetic alterations that do not occur in all cancer types, metabolic alterations are more common among cancer subtypes and across cancers. Recognizing cancer as a metabolic disorder could unravel key diagnostic and treatments markers that can impact approaches used in cancer management.

Citing Articles

Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.

Wan Y, Li G, Cui G, Duan S, Chang S Mol Cancer. 2025; 24(1):74.

PMID: 40069775 PMC: 11895238. DOI: 10.1186/s12943-025-02263-4.

Deciphering the metabolic landscape of colorectal cancer through the lens of AhR-mediated intestinal inflammation.

Swain J, Preeti , Mohanty C, Bajoria A, Patnaik S, Ward Gahlawat A Discov Oncol. 2025; 16(1):275.

PMID: 40053174 PMC: 11889322. DOI: 10.1007/s12672-025-01949-x.

Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma.

Yuan L, Yue Z, Ma Q, Zhang P, Xiao F, Chen L Front Immunol. 2025; 16:1528853.

PMID: 40051634 PMC: 11882876. DOI: 10.3389/fimmu.2025.1528853.

[Integrative transcriptomics-metabolomics approach to identify metabolic pathways regulated by glutamine synthetase activity].

Ling T, Shi J, Feng T, Pei S, Li S, Piao H Se Pu. 2025; 43(3):207-219.

PMID: 40045642 PMC: 11883535. DOI: 10.3724/SP.J.1123.2024.04003.

Advances in sodium-glucose transporter protein 2 inhibitors and tumors.

Wang J, Yang W Front Oncol. 2025; 15:1522059.

PMID: 40007997 PMC: 11850236. DOI: 10.3389/fonc.2025.1522059.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Baenke F, Peck B, Miess H, Schulze A . Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013; 6(6):1353-63. PMC: 3820259. DOI: 10.1242/dmm.011338. View

Chmurzynska A . The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006; 47(1):39-48. DOI: 10.1007/BF03194597. View

Marshall L, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O . Tumors establish resistance to immunotherapy by regulating T recruitment via CCR4. J Immunother Cancer. 2020; 8(2). PMC: 7692993. DOI: 10.1136/jitc-2020-000764. View

Pepino M, Kuda O, Samovski D, Abumrad N . Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014; 34:281-303. PMC: 4329921. DOI: 10.1146/annurev-nutr-071812-161220. View

Wang X, Sun Q . TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2016; 8(1):624-643. PMC: 5352183. DOI: 10.18632/oncotarget.13483. View

Taira T, Maeda J, Onishi T, Kitaura H, Yoshida S, Kato H . AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC. Genes Cells. 1998; 3(8):549-65. DOI: 10.1046/j.1365-2443.1998.00206.x. View

Fhu C, Ali A . Fatty Acid Synthase: An Emerging Target in Cancer. Molecules. 2020; 25(17). PMC: 7504791. DOI: 10.3390/molecules25173935. View

Annibaldi A, Widmann C . Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care. 2010; 13(4):466-70. DOI: 10.1097/MCO.0b013e32833a5577. View

10.

Liu F, Liu W, Zhou S, Yang C, Tian M, Jia G . Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer. 2020; 8(2). PMC: 7332195. DOI: 10.1136/jitc-2019-000501. View

11.

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

12.

Abumrad N, Coburn C, Ibrahimi A . Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm. Biochim Biophys Acta. 1999; 1441(1):4-13. DOI: 10.1016/s1388-1981(99)00137-7. View

13.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

14.

Shanware N, Mullen A, DeBerardinis R, Abraham R . Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl). 2011; 89(3):229-36. DOI: 10.1007/s00109-011-0731-9. View

15.

Lee W, Jiang Z, Liu J, Haverty P, Guan Y, Stinson J . The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465(7297):473-7. DOI: 10.1038/nature09004. View

16.

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

17.

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

18.

Xue L, Qi H, Zhang H, Ding L, Huang Q, Zhao D . Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. Front Oncol. 2020; 10:1510. PMC: 7472741. DOI: 10.3389/fonc.2020.01510. View

19.

Martinez-Outschoorn U, Peiris-Pages M, Pestell R, Sotgia F, Lisanti M . Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017; 14(2):113. DOI: 10.1038/nrclinonc.2017.1. View

20.

Shimano H . Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001; 40(6):439-52. DOI: 10.1016/s0163-7827(01)00010-8. View